Monitor for updates on strategic alternatives, as the company continues exploring potential transactions. The narrowing loss and revenue growth provide some stability, but the lack of a timeline suggests any outcome may be months away.
Price Chart
Executive Summary
TherapeuticsMD reported full-year 2025 financial results showing improved net loss of $(0.7)M (from $(2.3)M in 2024) and 71.6% YoY growth in license revenue to $3.0M. The company continues evaluating strategic alternatives with no timeline for completion.
Key Financial Metrics
Key Facts
- Net loss from continuing operations was $(0.7)M in 2025 vs $(2.3)M in 2024
- License revenue increased 71.6% YoY to $3.0M in 2025 from $1.8M in 2024
- Total operating expenses decreased 5.9% to $7.4M in 2025 from $7.9M in 2024
- Company continues evaluating strategic alternatives including potential acquisition, merger, or sale of assets
- Cash and cash equivalents totaled $7.5M as of December 31, 2025
Financial Impact
License revenue grew 71.6% to $3.0M while net loss narrowed by $1.6M year-over-year
Risk Factors
- Company has ongoing disputes with Mayne Pharma that could impact royalty revenues
- Ability to continue as a going concern is uncertain according to risk factors
- Company's ability to remain listed on Nasdaq is a risk factor
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-036519 |
| Document: ea028323901ex99-1.htm | 0001213900-26-036519 |
| Document: 0001213900-26-036519-index-headers.html | 0001213900-26-036519 |
| Document: 0001213900-26-036519-index.html | 0001213900-26-036519 |
| Document: 0001213900-26-036519.txt | 0001213900-26-036519 |
| 8-K Data (Synthetic) | 0001213900-26-036519 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $2.08 $2.10 | ▼ −0.96% | ▼ −2.86% | $1.80 (+13.46%) |
May 12, 2026 23w ago | 8-K | $2.02 $1.82 | ▼ −9.90% | ▼ −9.29% | $1.80 (−10.89%) |
Mar 31, 2026 29w ago | 10-K/A | $2.00 $2.11 | ▼ −5.50% | ▲ +4.22% | $1.80 (+10.00%) |
Mar 30, 2026 30w ago | 8-K | $2.02 $2.10 | ▲ +3.96% | ▼ −5.46% | $1.80 (−10.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers